This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-mesothelin scFv to the C terminus of the p35 subunit of IL12 through a short linker (GSADGG). It was expressed in CHO and purified with affinity chromatography. The immunocytokine retains the ability to bind the mesothelin as well as the biological activity of IL12. The immunocytokine retained sufficient bioactivity of IL12 and significantly inhibited human malignant mesothelioma (NCI-H226) grown in the peritoneal cavity of nude mice and showed comparable anti-tumor activity to that of the SS1P immunotoxin. This immunocytokine was designed for treating mesothelin-positive tumors.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
NABL-009 | Recombinant Anti-human MSLN VHH Single Domain Antibody | WB, IHC, FC, FuncS | Llama VHH |
HPAB-M0391-YC | Recombinant Llama Anti-MSLN Single Domain Antibody (HPAB-M0391-YC) | ELISA, FC, IF | Llama VHH |
HPAB-M0392-YC | Recombinant Llama Anti-MSLN Single Domain Antibody (HPAB-M0392-YC) | ELISA, FC, IF | Llama VHH |
There are currently no Customer reviews or questions for ACFP-SH061. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.